Mesoblast Dirección

Dirección controles de criterios 4/4

El CEO de Mesoblast's es Silviu Itescu , nombrado en Jan 2011, tiene una permanencia de 13.25 años. compensación anual total es $1.11M, compuesta por 60.6% salario y 39.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 6.92% de las acciones de la empresa, por valor de $47.08M. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 5.8 años, respectivamente.

Información clave

Silviu Itescu

Chief Executive Officer (CEO)

US$1.1m

Compensación total

Porcentaje del salario del CEO	60.6%
Permanencia del CEO	13.3yrs
Participación del CEO	6.9%
Permanencia media de la dirección	4.6yrs
Promedio de permanencia en la Junta Directiva	5.9yrs

Actualizaciones recientes de la dirección

Recent updates

Mesoblast Limited: Back From The Dead

Apr 10

Mesoblast GAAP EPS of -$0.14, revenue of $10.21M

Aug 31

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Apr 30

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Dec 15

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Dec 02

Mesoblast EPS beats by $0.22, misses on revenue

Nov 19

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Silviu Itescu en comparación con los beneficios de Mesoblast?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$73m
Sep 30 2023	n/a	n/a	-US$81m
Jun 30 2023	US$1m	US$673k	-US$82m
Mar 31 2023	n/a	n/a	-US$81m
Dec 31 2022	n/a	n/a	-US$84m
Sep 30 2022	n/a	n/a	-US$86m
Jun 30 2022	US$1m	US$697k	-US$91m
Mar 31 2022	n/a	n/a	-US$92m
Dec 31 2021	n/a	n/a	-US$97m
Sep 30 2021	n/a	n/a	-US$97m
Jun 30 2021	US$2m	US$757k	-US$99m
Mar 31 2021	n/a	n/a	-US$109m
Dec 31 2020	n/a	n/a	-US$98m
Sep 30 2020	n/a	n/a	-US$97m
Jun 30 2020	US$2m	US$697k	-US$78m
Mar 31 2020	n/a	n/a	-US$66m
Dec 31 2019	n/a	n/a	-US$76m
Sep 30 2019	n/a	n/a	-US$76m
Jun 30 2019	US$1m	US$709k	-US$90m
Mar 31 2019	n/a	n/a	-US$90m
Dec 31 2018	n/a	n/a	-US$86m
Sep 30 2018	n/a	n/a	-US$48m
Jun 30 2018	US$2m	US$748k	-US$35m
Mar 31 2018	n/a	n/a	-US$42m
Dec 31 2017	n/a	n/a	-US$30m
Sep 30 2017	n/a	n/a	-US$64m
Jun 30 2017	US$1m	US$776k	-US$77m

Compensación vs. Mercado: La compensación total de Silviu($USD1.11M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD3.44M).

Compensación vs. Ingresos: La compensación de Silviu ha sido consistente con los resultados de la empresa en el último año.

CEO

Silviu Itescu (66 yo)

13.3yrs

Permanencia

US$1,109,634

Compensación

Prof. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACRA, FTSE has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesobla...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Silviu Itescu	Founder	13.3yrs	US$1.11m	6.92% $ 56.4m
Eric Rose	Chief Medical Officer & Executive Director	2.3yrs	US$1.02m	sin datos
Andrew Chaponnel	Interim Chief Finance Officer	2.8yrs	sin datos	sin datos
Peter Howard	General Counsel & Corporate Executive	12.8yrs	sin datos	sin datos
Roger Brown	Head of Spinal Orthopedic Disorders	8.6yrs	sin datos	sin datos
Michael Schuster	Head of Pharma Partnering	no data	sin datos	sin datos
Geraldine Storton	Head of Regulatory Affairs & Quality Management	no data	sin datos	sin datos
Justin Horst	Head of Manufacturing	no data	sin datos	sin datos
Niva Sivakumar	Joint Company Secretary	4.6yrs	sin datos	sin datos
Paul Hughes	Joint Company Secretary	2.1yrs	sin datos	sin datos
Kenneth Borow	Executive	no data	sin datos	sin datos

4.6yrs

Permanencia media

66yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MESO se considera experimentado (4.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Silviu Itescu	Founder	16.9yrs	US$1.11m	6.92% $ 56.4m
Eric Rose	Chief Medical Officer & Executive Director	11.1yrs	US$1.02m	sin datos
Philip Facchina	Independent Non-Executive Director	3.2yrs	US$135.62k	0.022% $ 176.0k
Joseph Swedish	Independent Non-Executive Chairman	5.9yrs	US$247.95k	0.040% $ 328.2k
William A. Burns	Independent Non-Executive Vice Chairman	10.2yrs	US$132.70k	0.0093% $ 75.9k
Henry Krum	Member of Scientific Advisory Board	no data	sin datos	sin datos
Joseph Lane	Member of Scientific Advisory Board	no data	sin datos	sin datos
Robert Graham	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jane Bell	Independent Non-Executive Director	1.8yrs	US$139.29k	0.048% $ 388.2k
Richard Gilbert	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stephen Graves	Member of Scientific Advisory Board	no data	sin datos	sin datos
Philip Krause	Non Executive Director	2.2yrs	US$138.33k	0.034% $ 276.8k

5.9yrs

Permanencia media

71yo

Promedio de edad

Junta con experiencia: La junta directiva de MESO se considera experimentada (5.8 años de antigüedad promedio).

Mesoblast Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Executive Changes

Recent updates

Mesoblast Limited: Back From The Dead

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Mesoblast GAAP EPS of -$0.14, revenue of $10.21M

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Mesoblast Limited Provides Litigation Update

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Mesoblast Limited Announces Executive Changes

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer

Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

Mesoblast Provides Update Following Meeting with FDA’s OTAT on Remestemcel-L for Children with Acute Graft Versus Host Disease

Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L

Mesoblast Limited announced that it expects to receive $90 million in funding from Oaktree Capital Management, L.P.

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal

Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding

Mesoblast Limited Announces Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-Covid-19 Published in Pediatrics

Mesoblast Limited Announces Results from the Phase 3 Randomized Controlled Trial of Its Allogeneic Mesenchymal Precursor Cell Therapy

Mesoblast issues FQ2 operational and financial update

Mesoblast Limited Presents Heart Failure Phase 3 Trial Results At Investor Healthcare Conference

Mesoblast Limited Announces Additional Results from the Landmark Dream-Hf Randomized Controlled Phase 3 Trial in 537 Treated Patients with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction (HFrEF) Who Received Rexlemestrocel-L (REVASCOR) or Control Sham

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Mesoblast: The Future Looks Bleak

Mesoblast Limited Announces Update on Covid-19 ARDS Trial

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Mesoblast Limited Announces United States Food and Drug Administration Granted Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to Covid-19 Infection

Mesoblast Limited Announces FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Mesoblast Limited announced that it expects to receive $25 million in funding from Novartis AG

Mesoblast Limited Enters into an Exclusive Worldwide License and Collaboration Agreement with Novartis for the Development, Manufacture and Commercialization of Remestemcel-L

Mesoblast EPS beats by $0.22, misses on revenue

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been File Against Precigen, Royal Caribbean, Mesoblast and Loop Industries

The Law Offices of Frank R. Cruz Announces Class Action Lawsuit Against Mesoblast Limited

Rosen Law Firm Reminds Mesoblast Limited Investors of Important Deadline

Mesoblast Limited Announces Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Mesoblast Limited

Mesoblast Limited Announces US Food and Drug Administration Issues Complete Response Letter to its Biologics License Application

Mesoblast Limited Announces Updates on RYONCIL

Mesoblast Limited Receives Complete Response Letter from US Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Auditor Raises 'Going Concern' Doubt

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.33959 million.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media